Literature DB >> 27271927

Aberrant Methylation of FOXE1 Contributes to a Poor Prognosis for Patients with Colorectal Cancer.

Keishi Sugimachi1,2, Tae Matsumura1,3, Teppei Shimamura4, Hidenari Hirata1, Ryutaro Uchi1, Masami Ueda1, Shotaro Sakimura1, Tomohiro Iguchi1, Hidetoshi Eguchi1, Takaaki Masuda1, Kazutoyo Morita2, Kenji Takenaka2, Yoshihiko Maehara5, Masaki Mori3, Koshi Mimori6.   

Abstract

BACKGROUND: Hypermethylation of DNA silences gene expression and is an important event in colorectal cancer (CRC). This study aimed to identify aberrantly methylated genes that contribute to a poor prognosis for patients with CRC.
METHODS: The study comprehensively explored DNA methylation microarray profiles from 396 CRC samples and 45 normal control samples in a database and selected aberrantly methylated transcription factors associated with prognosis and metastasis. Using quantitative reverse transcription polymerase chain reaction, the identified genes in 140 patients with CRC were validated to assess the relationship between expression of methylated genes and prognosis.
RESULTS: In the study, FOXE1 was newly identified as a gene associated with prognosis and metastasis in CRC. Expression of FOXE1 in CRC tissues was significantly lower than in normal colorectal tissues (p = 0.01). The survival rate for the patients with low expression of FOXE1 was significantly lower than that for patients with high expression of FOXE1 in uni- and multivariate analyses. Inhibition of DNA methylation recovered FOXE1 expression in CRC cells.
CONCLUSIONS: Methylation-mediated silencing of FOXE1 expression was shown to be a potential prognostic factor in CRC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27271927     DOI: 10.1245/s10434-016-5289-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

Review 1.  Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives.

Authors:  Hege Marie Vedeld; Ajay Goel; Guro E Lind
Journal:  Semin Cancer Biol       Date:  2017-12-15       Impact factor: 15.707

2.  The Expression of FOXE-1 and STIP-1 in Papillary Thyroid Carcinoma and Their Relationship with Patient Prognosis.

Authors:  Enas M Fouad; Ola A Harb; Salem Reham Amin; Ola M El Farargy; Fady M Habib; Loay M Gertallah
Journal:  Iran J Pathol       Date:  2018-07-17

Review 3.  The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis.

Authors:  Paul Laissue
Journal:  Mol Cancer       Date:  2019-01-08       Impact factor: 27.401

4.  FOXE1 represses cell proliferation and Warburg effect by inhibiting HK2 in colorectal cancer.

Authors:  Weixing Dai; Xianke Meng; Shaobo Mo; Wenqiang Xiang; Ye Xu; Long Zhang; Renjie Wang; Qingguo Li; Guoxiang Cai
Journal:  Cell Commun Signal       Date:  2020-01-09       Impact factor: 5.712

5.  FOXE1 regulates migration and invasion in thyroid cancer cells and targets ZEB1.

Authors:  Jesús Morillo-Bernal; Lara P Fernández; Pilar Santisteban
Journal:  Endocr Relat Cancer       Date:  2020-03       Impact factor: 5.678

6.  Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.

Authors:  Thomas Sanford; Maxwell V Meng; Reema Railkar; Piyush K Agarwal; Sima P Porten
Journal:  Clin Epigenetics       Date:  2018-02-12       Impact factor: 6.551

7.  Transcriptional landscape of the embryonic chicken Müllerian duct.

Authors:  Zahida Yesmin Roly; Rasoul Godini; Martin A Estermann; Andrew T Major; Roger Pocock; Craig A Smith
Journal:  BMC Genomics       Date:  2020-10-02       Impact factor: 3.969

8.  Integrative Analysis of DNA Methylation and Gene Expression Profiles Identifies Colorectal Cancer-Related Diagnostic Biomarkers.

Authors:  Mingyue Xu; Lijun Yuan; Yan Wang; Shuo Chen; Lin Zhang; Xipeng Zhang
Journal:  Pathol Oncol Res       Date:  2021-07-21       Impact factor: 2.874

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.